Reference : NF-kappa B: a new player in angiostatic therapy.
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
NF-kappa B: a new player in angiostatic therapy.
Tabruyn, Sébastien mailto [Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire >]
Griffioen, Arjan W [> > > >]
Kluwer Academic Publishers
Yes (verified by ORBi)
The Netherlands
[en] Angiogenesis Inhibitors/therapeutic use ; Animals ; Humans ; NF-kappa B/drug effects/physiology ; Neovascularization, Pathologic/drug therapy/metabolism ; Signal Transduction/drug effects/physiology
[en] Angiogenesis is considered a promising target in the treatment of cancer. Most of the angiogenesis inhibitors in late-stage clinical testing or approved for the treatment of cancer act indirectly on endothelial cells. They either neutralize angiogenic growth factors from the circulation or block the signaling pathways activated by these growth factors. Another group of angiogenesis inhibitors are the direct angiostatic compounds. These agents have a direct effect on the endothelium, affecting cellular regulatory pathways, independently of the tumor cells. The reason that this category of agents is lagging behind regarding their translation to the clinic may be the lack of sufficient knowledge on the mechanism of action of these compounds. The transcription factor NF-kappaB has been recently connected with multiple aspects of angiogenesis. In addition, several recent studies report that angiogenesis inhibition is associated to NF-kappaB activation. This is of special interest since in tumor cells NF-kappaB activation has been associated to inhibition of apoptosis and currently novel treatment strategies are being developed based on inhibition of NF-kappaB. The paradigm that systemic NF-kappaB inhibition can serve as an anti-cancer strategy, therefore, might need to be re-evaluated. Based on recent data, it might be speculated that NF-kappaB activation, when performed specifically in endothelial cells, could be an efficient strategy for the treatment of cancer.

File(s) associated to this reference

Fulltext file(s):

Restricted access
BBRC.pdfPublisher postprint128.45 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.